Lenalidomide Sandoz

Lenalidomide, the active ingredient in Lenalidomide Sandoz, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is employed in the treatment of multiple myeloma and myelodysplastic syndromes, primarily in adult patients. The medication works by modulating immune function and inhibiting tumor blood vessel formation.

GNH USA supplies Lenalidomide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with established quality assurance processes and regulatory compliance across multiple regions.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders. - Multiple myeloma: improves progression‑free survival and overall response rates in adult patients. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle cell lymphoma (in combination therapy): contributes to tumor control in adult patients.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels leading to easy bruising. - Diarrhea: mild to moderate gastrointestinal upset. - Rash: skin irritation or erythema. - Nausea: occasional upset stomach. Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia with infection: heightened susceptibility to serious infections. - Secondary primary malignancies: emergence of new cancers. - Hepatic toxicity: elevated liver enzymes or liver injury. - Severe skin reactions (e.g., Stevens‑Johnson syndrome): extensive skin detachment. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Lenalidomide requires careful monitoring and specific safety measures. - Pregnancy: contraindicated (Category X); avoid use in pregnant women. - Thrombosis risk: assess and consider prophylaxis in patients with additional risk factors. - Hematologic monitoring: perform regular CBC to detect cytopenias. - Renal impairment: adjust dosing and monitor renal function. - Drug interactions: avoid concomitant use with strong CYP inducers without supervision. - Store at ambient temperature: keep in original container, protect from moisture and light.

Lenalidomide may interact with several medicines; clinicians should review patient regimens. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased bleeding risk. - Live vaccines: heightened infection risk due to immunosuppression. Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may increase plasma levels. - H2 antagonists (e.g., ranitidine): may affect absorption. - Concomitant chemotherapy agents (e.g., melphalan): additive myelosuppression.